A new trading day began on Monday, with Phathom Pharmaceuticals Inc (NASDAQ: PHAT) stock price up 3.47% from the previous day of trading, before settling in for the closing price of $8.35. PHAT’s price has ranged from $2.21 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.50% over the past five years. Meanwhile, its annual earnings per share averaged 41.47%. With a float of $37.85 million, this company’s outstanding shares have now reached $69.64 million.
Let’s look at the performance matrix of the company that is accounted for 427 employees. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.
Phathom Pharmaceuticals Inc (PHAT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 45.79%, while institutional ownership is 47.37%. The most recent insider transaction that took place on Jul 16 ’25, was worth 14,152. In this transaction Principal Accounting Officer of this company sold 1,692 shares at a rate of $8.36, taking the stock ownership to the 48,392 shares. Before that another transaction happened on May 21 ’25, when Company’s Director bought 3,780 for $3.86, making the entire transaction worth $14,609. This insider now owns 59,403 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.47% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Here are Phathom Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -0.42 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 0.73 million, a negative change from its year-to-date volume of 1.82 million. As of the previous 9 days, the stock’s Stochastic %D was 35.21%.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 63.60%, which indicates a significant increase from 42.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was lower than the 0.68 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.20, while its 200-day Moving Average is $7.73.